Prime Medicine Appoints Allan Reine, M.D., as Chief Financial Officer
05 1월 2024 - 10:00PM
Prime Medicine, Inc. (Nasdaq: PRME), a biotechnology company
committed to delivering a new class of differentiated one-time
curative genetic therapies, today announced the appointment of
Allan Reine, M.D., as the Company’s Chief Financial Officer,
effective January 17, 2024. A seasoned financial executive with
over twenty years’ experience in the biotechnology industry, Dr.
Reine will be responsible for the company’s financing strategy and
investor relations, and will oversee all financial operations as
Prime Medicine begins its transition into a clinical company.
“I am delighted to welcome Allan to Prime Medicine. He brings
tremendous financial, operational and leadership experience in the
life sciences space, as well as a proven track record developing
and implementing multi-pronged strategies to finance a diverse
pipeline and broad platform,” said Keith Gottesdiener, M.D.,
President and Chief Executive Officer of Prime Medicine. “We look
forward to his many contributions as we advance our lead programs
toward the clinic, leverage the modularity of our Prime Editing
technology to address a wide range of diseases and, ultimately,
execute on our vision of delivering the promise of one-time,
curative genetic therapies to patients worldwide.”
Prior to joining Prime Medicine, Dr. Reine was Chief Financial
Officer at Foghorn Therapeutics and, before that, at Pieris
Pharmaceuticals. Dr. Reine also serves as Chairman of the Board of
ONK Therapeutics. Previously, Dr. Reine managed various healthcare
portfolios primarily focused on biotechnology and pharmaceutical
companies at Lombard Odier Asset Management, Citi Principal
Strategies, SAC Capital, Trivium Capital and Alexandra Investment
Management. He started his career at CIBC World Markets where he
worked in both biotechnology investment banking and biotechnology
equity research. Dr. Reine received his M.D. from the University of
Toronto, and his Bachelor of Science in statistical sciences from
the University of Western Ontario.
“Now is an incredibly exciting time to join Prime Medicine. The
Company’s recently announced preclinical data supports Prime
Editing’s tremendous versatility and highly differentiated safety
profile and creates strategic optionality for maximizing the
potential of this technology,” said Dr. Reine. “I am eager to
partner with the team as Prime Medicine begins its transition into
a clinical-stage company in 2024, while driving strategic
investment in programs and delivery technologies that could treat
many more patients, including those living with hematologic and
immunologic conditions, as well as liver, ocular and neuromuscular
diseases.”
About Prime MedicinePrime Medicine is a leading
biotechnology company dedicated to creating and delivering the next
generation of gene editing therapies to patients. The Company is
leveraging its proprietary Prime Editing platform, a versatile,
precise and efficient gene editing technology, to develop a new
class of differentiated, one-time, potentially curative genetic
therapies. Designed to make only the right edit at the right
position within a gene while minimizing unwanted DNA modifications,
Prime Editors have the potential to repair almost all types of
genetic mutations and work in many different tissues, organs and
cell types.
Prime Medicine is currently progressing a diversified portfolio
of eighteen programs initially focused on genetic diseases with a
fast, direct path to treating patients or with a high unmet need
because they cannot be treated using other gene-editing approaches.
Over time, the Company intends to maximize Prime Editing’s
therapeutic potential and advance potentially curative therapeutic
options to patients for a broad spectrum of diseases. For more
information, please visit www.primemedicine.com.
© 2023 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE,
the Prime Medicine logos, and PASSIGE are trademarks of Prime
Medicine, Inc. All other trademarks referred to herein are the
property of their respective owners.
Forward Looking StatementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended,
including, without limitation, implied and express statements about
Prime Medicine’s beliefs and expectations regarding: Dr. Reine’s
appointment as chief financial officer, and its potential impacts
on the Company, and the initiation, timing, progress, and results
of its research and development programs, preclinical studies and
future clinical trials, and the release of data related thereto,
including the transition of Prime Medicine to a clinical
company, leveraging the modularity of Prime Editing technology to
address a wide range of diseases, and executing on a vision of
delivering the promise of one-time, curative genetic therapies to
patients worldwide. The words “may,” “might,” “will,” “could,”
“would,” “should,” “expect,” “plan,” “anticipate,” “intend,”
“believe,” “expect,” “estimate,” “seek,” “predict,” “future,”
“project,” “potential,” “continue,” “target” and similar words or
expressions are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words.
Any forward-looking statements in this press release are based
on management’s current expectations and beliefs and are subject to
a number of risks, uncertainties and important factors that may
cause actual events or results to differ materially from those
expressed or implied by any forward-looking statements contained in
this press release, including the risks and uncertainties described
in the section entitled “Risk Factors” in Prime Medicine’s most
recent Annual Report on Form 10-K, as well as any subsequent
filings with the Securities and Exchange Commission. In addition,
any forward-looking statements represent Prime Medicine’s views
only as of today and should not be relied upon as representing its
views as of any subsequent date. Prime Medicine explicitly
disclaims any obligation to update any forward-looking statements
subject to any obligations under applicable law. No representations
or warranties (expressed or implied) are made about the accuracy of
any such forward-looking statements.
Investor ContactHannah DeresiewiczStern
Investor Relations,
Inc.212-362-1200hannah.deresiewicz@sternir.com
Media ContactDan Budwick,
1ABdan@1ABmedia.com
Prime Medicine (NASDAQ:PRME)
과거 데이터 주식 차트
부터 4월(4) 2024 으로 5월(5) 2024
Prime Medicine (NASDAQ:PRME)
과거 데이터 주식 차트
부터 5월(5) 2023 으로 5월(5) 2024